Applying an equity lens to interventions: using PROGRESS ensures consideration of socially stratifying factors to illuminate inequities in health
10.1016/j.jclinepi.2013.08.005 · doi-reference
Measuring inconsistency in meta-analyses
10.1136/bmj.327.7414.557 · doi-reference
Synthesis without meta-analysis (SWiM) in systematic reviews: reporting guideline
10.1136/bmj.l6890 · doi-reference
A comparison of heterogeneity variance estimators in simulated random-effects meta-analyses
10.1002/jrsm.1316 · doi-reference
Development and validation of improved algorithms for the assessment of global cardiovascular risk in women
10.1001/jama.297.6.611 · doi-reference
Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study
10.1136/bmj.j2099 · doi-reference
RoB 2: a revised tool for assessing risk of bias in randomised trials
10.1136/bmj.l4898 · doi-reference
Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide
10.1136/bmj.g1687 · doi-reference
PRESS peer review of electronic search strategies: 2015 guideline statement
10.1016/j.jclinepi.2016.01.021 · doi-reference
2. Diagnosis and classification of diabetes: standards of care in diabetes-2025
10.2337/dc25-s002 · doi-reference
Diagnosis and management of the metabolic syndrome
10.1161/circulationaha.105.169404 · doi-reference
Meta-analyses involving cross-over trials: methodological issues
10.1093/ije/31.1.140 · doi-reference
The PRISMA 2020 statement: an updated guideline for reporting systematic reviews
10.1136/bmj.n71 · doi-reference
Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation
10.1136/bmj.g7647 · doi-reference
Association of low-density lipoprotein testing after an atherosclerotic cardiovascular event with subsequent statin adherence and intensification
10.1016/j.amjmed.2021.11.011 · doi-reference
Association between lipid testing and statin adherence in the veterans affairs health system
10.1016/j.amjmed.2019.04.002 · doi-reference
Follow-up lipid tests and physician visits are associated with improved adherence to statin therapy
10.2165/00019053-200422003-00003 · doi-reference
Patterns of serum laboratory monitoring for safety and efficacy in patients on chronic statin therapy
10.1177/2042098612474293 · doi-reference
Screening for statin-related toxicity
10.1001/archinte.163.6.688 · doi-reference
2025 focused update of the 2019 ESC/EAS guidelines for the management of dyslipidaemias
10.1093/eurheartj/ehaf190 · doi-reference
2021 Canadian Cardiovascular Society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in adults
10.1016/j.cjca.2021.03.016 · doi-reference
Monitoring of lipids, enzymes, and creatine kinase in patients on lipid-lowering drug therapy
10.1007/s11886-013-0397-8 · doi-reference
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins
10.1016/s0140-6736(05)67394-1 · doi-reference
2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk
10.1093/eurheartj/ehz455 · doi-reference
Global, regional, and national burden of cardiovascular diseases and risk factors in 204 countries and territories, 1990-2023
10.1016/j.jacc.2025.08.015 · doi-reference
